Last €77.91 EUR
Change Today +0.91 / 1.18%
Volume 0.0
HOS On Other Exchanges
New York
As of 11:27 AM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HOS) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/5/15 - €78.73
52 Week Low
03/27/14 - €29.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HOSPIRA INC (HOS)

hospira inc (HOS) Details

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of patients with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a nonsteroidal anti-inflammatory drug analgesic. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

19,000 Employees
Last Reported Date: 02/12/15
Founded in 2003

hospira inc (HOS) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.0M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $464.7K
Senior Vice President of Operations
Total Annual Compensation: $432.5K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $444.6K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $429.8K
Compensation as of Fiscal Year 2013.

hospira inc (HOS) Key Developments

Hospira Launches Remicade Biosimilar Inflectra in Additional European Countries

Hospira announced that it is launching its Remicade biosimilar Inflectra in at least 10 new European markets, nearly doubling the product's presence on the continent. Inflectra (infliximab) is the first biosimilar monoclonal antibody to be marketed in Europe, will soon be available in Austria, Sweden, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands and Spain. Inflectra mimics Janssen's Remicade (infliximab), which treats inflammatory diseases such as psoriatic and rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, plaque psoriasis and ulcerative colitis.

Shareholders Foundation Announces Investor Lawsuit Against Acquisition of Hospira, Inc

The Shareholders Foundation Inc. announced that an investor, who currently holds shares of Hospira Inc., filed a lawsuit in effort to stop the proposed takeover of Hospira Inc. by Pfizer for $90 per share. The plaintiff alleges that the defendants breached their fiduciary duties owed to stockholders by agreeing to sell Hospira Inc. too cheaply via an unfair process to Pfizer Inc. On February 5, 2015, Pfizer Inc. and Hospira Inc. announced that they have entered into a merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion. However, the plaintiff claims that the $90-offer is too low and undervalues Hospira Inc. In addition, the plaintiff claims that the process is also unfair to stockholders.

Hospira Inc. Launches First Biosimilar Monoclonal Antibody Inflectra in Major European Markets

Hospira Inc. announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets. Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn's disease, adult and paediatric ulcerative colitis and plaque psoriasis. Biologic medicines have transformed the lives of people living with chronic inflammatory conditions, such as RA and inflammatory bowel disease (IBD). However, biologics are responsible for some of the biggest medicinal costs across Europe and these high costs can restrict access to treatment. For example, it has been estimated that 40% of RA patients in Europe have severely restricted access to biologic treatment. Inflectra can offer a cost-effective alternative while maintaining the same quality, safety and efficacy as the reference product. Infliximab is a cornerstone treatment for many inflammatory diseases, with over 15 years' worth of clinical data and experience. Inflectra is a biosimilar medicine to the reference product, Remicade (infliximab), and is the first biosimilar mAb to be approved by the European Commission (EC). A biosimilar developed in-line with EU requirements can be considered a therapeutic alternative to an existing biologic. Inflectra received its license from the EC in September 2013, following adoption of the EMA Committee for Medicinal Products for Human Use (CHMP) positive recommendation for granting marketing authorization. Review by the EMA included detailed analysis of biophysical properties and safety, efficacy and tolerability data from an extensive preclinical and clinical trial program. In a phase III randomized, double-blind study involving 606 patients, Inflectra met its primary endpoint of therapeutic equivalence to Remicade. In this study, using the ACR20 scoring system, 73.4% of patients receiving Inflectra achieved a greater than or equal to 20% improvement in RA symptoms after 30 weeks of treatment, compared with 69.7% treated with Remicade. In the same study, 42.3% of patients receiving Inflectra achieved a greater than or equal to 50% improvement in RA symptoms after 30 weeks of treatment (measured using the ACR50 scoring system), compared with 40.6% treated with Remicade. Comparable safety and tolerability data also demonstrated Inflectra's equivalence to Remicade. There were no marked differences in the immunogenicity profile of the two products up to 54 weeks, and the impact of anti-drug antibodies on efficacy and safety was comparable. Inflectra is being launched in several major European markets, including Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, Netherlands, Spain and Sweden. With the launch of the product in these new markets, Inflectra is now available in 24 European countries. Hospira's partner, Celltrion, has also submitted an application to the U.S. Food and Drug Administration for biosimilar infliximab. With one of the biosimilar pipelines in the industry, Hospira has more than seven years' of market experience in biosimilars. The company has several biosimilars on the European market, including Inflectra (infliximab), Retacrit™ (epoetin zeta) and Nivestim™ (filgrastim). Hospira has delivered more than 10 million doses of biosimilar medicines to patients worldwide.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HOS:GR €77.91 EUR +0.91

HOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $60.21 USD -0.01
Chugai Pharmaceutical Co Ltd ¥3,590 JPY +30.00
Cintas Corp $84.01 USD +0.31
UCB SA €69.61 EUR +1.05
Zimmer Holdings Inc $121.33 USD +0.81
View Industry Companies

Industry Analysis


Industry Average

Valuation HOS Industry Range
Price/Earnings 44.8x
Price/Sales 3.3x
Price/Book 4.5x
Price/Cash Flow 44.9x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at